In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


The Evolution of E-Empowered Consumer Marketing

Executive Summary

Effective consumer web sites balance straightforward ads with customized disease management--and eventually bring the physician into the corporate-consumer dialog.

You may also be interested in...

Cyberizing the Rep: Can E-Marketing Solve Pharma's Promotional Dilemma?

Drug marketing is increasingly expensive and decreasingly productive. WebMD Health, the dominant health portal, argues it is not merely another advertising forum, but a more effective influencer of consumer and physician behavior than detail reps and DTC promotion. So far, drug companies remain on the sidelines, having been burned once by similar arguments about the marketing value of neutral channels, represented by PBMs, of which many of WebMD's managers are alumnae.

Harnessing Interactive DTC to Drive Demand in Product Launch

Given the importance of a rapid launch of new products, many pharmaceutical firms are turning to consumer marketing tools to create consumer demand. To date, much of the consumer marketing effort has focused on direct-to-consumer advertising, but more and more drug companies are learning to harness the power of the Internet to push out their product message.Far more than simply establishing a web site, interactive DTC--or iDTC--marketing is a two-way approach whereby companies and consumers exchange information through feedback loops, the end result of which is to develop and deepen customer relationships. To be effective, however, iDTC campaigns must have a clear sense of the bottlenecks to product adoption, establish reasonable goals and expectations, and coordinate with and complement much more traditional launch strategies.

Amgen/AstraZeneca’s Tezepelumab Cuts Asthma Exacerbations By 56%

Data presented at AAAI meeting show reduced annualized asthma exacerbation rates across all patient populations, but doctors are unlikely to switch patients served well by existing biologics. 


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts